HXN-1022 / Earendil Labs - LARVOL DELTA

AI-Guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody (AAD 2026) - "It potently inhibits IL31 activity in IL31R-STAT and HaCaT assays, outperforming Nemolizumab and NM26-2198 analogues. Meanwhile, HXN-1022 exhibits robust in vitro activity for OX40L in the OX40-NFκB reporter assay, OX40L-induced PBMC activation, and Th2 differentiation experiments, with potency comparable to Amlitelimab... HXN-1022 is a first-in-class bsAb that simultaneously targets IL-31 and OX40L, two key drivers of inflammation and pruritus in skin disease. These findings support HXN-1022 as a promising therapeutic candidate for AD and other autoimmune skin disorders. HXN-1022 is currently under IND-enabling studies."

Bispecific • Preclinical • Atopic Dermatitis • Dermatitis • Graft versus Host Disease • Immunology • Inflammation • Pruritus • IL1R1 • TNFSF4

AI-Guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody (AAAAI 2026) - "It effectively inhibits IL31 biological activity in the IL31R-STAT reporter assay and HaCaT cell activation, with superior efficacy to the benchmarks, Nemolizumab and NM26-2198 analogs. For the OX40L arm, HXN-1022 significantly blocks OX40L-induced downstream signaling and PBMC activation, with potency comparable to Amlitelimab...The bsAb represents a highly promising therapeutic option for patients with autoimmune skin disorders. HXN-1022 is currently under IND-enabling studies."

Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Graft versus Host Disease • Immunology • Inflammation • Pruritus • IL1R1 • TNFSF4